CytoMed Therapeutics Limited is accelerating its international expansion
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, The company announced that its wholly-owned subsidiary established in 2020, Advance Cancer Centre Pte. Ltd., has changed its name to CytoMed International Pte. Ltd. (“CytoMed International”), effective May 6, 2026.
The name change reflects the Company’s renewed focus on exploring opportunities to expand its international footprint, including setting up joint ventures overseas, development of international medical tourism initiatives, appointment of ov...
